about
Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitisTargets for inhibition of hepatitis C virus replication.Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAARTHBV mutations in untreated HIV-HBV co-infection using genomic length sequencing.Origins and Evolution of Hepatitis B Virus and Hepatitis D Virus.Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.Cross contamination of the genomes in human/hamster cell hybrids by multiple short recombination events.Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance.Possible origins and evolution of the hepatitis B virus (HBV).In Vitro Studies Show that Sequence Variability Contributes to Marked Variation in Hepatitis B Virus Replication, Protein Expression, and Function Observed across GenotypesIn vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection.Single-Molecule Sequencing Reveals Complex Genome Variation of Hepatitis B Virus during 15 Years of Chronic Infection following Liver Transplantation.Hepatitis B amongst Immigrants from Myanmar: Genotypes and their Clinical Relevance.Antiviral drug resistance and hepatitis B: a continuing public health problem.Genotypic profiles of hepatitis B in African immigrants and their clinical relevance.Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.Molecular epidemiology of hepatitis delta virus in the Western Pacific region.Molecular virology of hepatitis B virus, sub-genotype C4 in northern Australian Indigenous populations.Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.A novel hepatitis B virus S gene insertion associated with reduced humoral immunity and diagnostic escape.Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.Molecular epidemiology of hepatitis B in the Indigenous people of northern Australia.ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.Epidemiology and phylogenetic analysis of hepatitis D virus infection in Australia.Sub-optimal protection against past hepatitis B virus infection where subtype mismatch exists between vaccine and circulating viral genotype in northern Australia.Quantification of HBV covalently closed circular DNA from liver tissue by real-time PCR.Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and MisunderstoodMolecular characterization of hepatitis B virus (HBV) in African children living in Australia identifies genotypes and variants associated with poor clinical outcomeA Divergent Hepatitis D-Like Agent in BirdsAnalysis of genomic-length HBV sequences to determine genotype and subgenotype reference sequencesTracing Ancient Human Migrations into Sahul Using Hepatitis B Virus GenomesThe evolution and clinical impact of hepatitis B virus genome diversity
P50
Q28375647-B44544BB-C780-48A7-A4C7-AB2F332E6A4DQ33868412-E6A18899-F78B-4923-B227-FA08C3A1557BQ34070485-8F1D73FE-546E-4229-9C98-A111EE0BFA65Q34112620-D124F676-8866-4F47-BFDC-F0F020AFB08EQ34507369-06DBBAB7-7A8C-4DC0-8BEB-35BA787031E7Q34674838-184623A2-420E-45EE-B9B2-8AD83808CA3AQ36795736-0AB8E73F-11BE-408F-9C3E-BA916889138CQ36956933-7E53BD74-9295-4CF6-BB11-F3DFC11C643EQ37158625-54554607-98C3-42FB-A703-DB8DD79BC27BQ38135202-F29A6AD6-A750-40A1-ADAC-A1213FA5AF2AQ38736225-64DB900D-691A-49D0-B8EE-9498618287F8Q39328819-FC1524EC-6671-4536-923E-CC1858998CA3Q39716344-46DEF27C-40BC-46E7-903F-08596732F710Q40051063-281B29EE-D635-4F62-AF52-A28E1F7A302DQ40213011-A41968F6-CB58-4B03-86F4-5988A1A12D78Q40445749-9EB5BC4F-4B61-4254-84D3-63322B4E7947Q40572262-A0D99A37-A324-4A7D-99A9-157DB9125AF3Q40765071-948C0209-27B6-45B6-B039-1E163595B12CQ41986565-2005B9B7-21A9-468D-A66E-E108B481F0D0Q42208543-0FDC677C-492C-4AE0-9E54-5628495285DBQ42229780-4469E8CA-B34F-4713-AC6B-E5EDDDD195D2Q43779173-2E089344-851B-41F0-ABDF-1D9AA7033CA3Q45346077-62976F98-0D11-41C1-AEF8-3EB031AF8FDFQ45375655-2D214589-4985-4DDD-A50C-844793EAF934Q45401258-D3853E0C-0D04-40AA-84B6-B269496A5084Q46197619-EC2982E4-6934-4AA3-A459-388CA85D1826Q50088394-4837B29B-AD45-436D-B1C5-06194807C328Q53682058-D38C52A2-921F-4E0D-B7E5-447A416A61BDQ54219034-0A5D4AC9-37CE-4286-8602-EAF944C1D8B0Q54731000-8975DF8C-2155-4BC8-90A3-BC89CE91EBE7Q59351581-BA4DA39E-545D-4025-A912-05A871828E84Q59358291-38EF82A5-CC41-4986-98FF-7C0DF79EAC4DQ60345944-30144C43-7761-49B3-95E3-D9A2A87D0724Q90062367-AA866FD7-5223-46AA-ACC7-4E2DADAB3901Q92269009-D647EF9D-86D4-4364-8D7C-E43DCC76E2DEQ95936549-049B6142-5CDE-492C-8D1F-F6B1CC79C7AC
P50
description
researcher ORCID ID = 0000-0002-8206-2664
@en
wetenschapper
@nl
name
M Littlejohn
@ast
M Littlejohn
@en
M Littlejohn
@es
M Littlejohn
@nl
type
label
M Littlejohn
@ast
M Littlejohn
@en
M Littlejohn
@es
M Littlejohn
@nl
prefLabel
M Littlejohn
@ast
M Littlejohn
@en
M Littlejohn
@es
M Littlejohn
@nl
P106
P1153
16233499900
P31
P496
0000-0002-8206-2664